I am a
Home I AM A Search Login

Papers of the Week

2021 Apr 01

J Clin Med



CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine.


Capi M, De Angelis V, De Bernardini D, De Luca O, Cipolla F, Lionetto L, Simmaco M, Martelletti P
J Clin Med. 2021 Apr 01; 10(7).
PMID: 33916043.


Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor ("gepants") and of a new class of medications called "Ditans". This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines. Evidences show that therapeutic approaches targeted to CGRP have the potential to transform the clinical management of migraine, even though its appropriate place has yet to be determined with accuracy.